Arcus Biosciences Inc
RCUSHealthcare|Biotechnology|USA
$28.92
-1.04 (-3.47%)
Tangible Book
$4.18
About
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Stock Price
+203.1%(1Y)
Pipeline Summary
55 total trials30
Phase 1
22
Phase 2
6
Phase 3
0
Phase 4
Completed: 21Recruiting: 10Terminated: 2Active: 17NOT_YET_RECRUITING: 2Withdrawn: 2SUSPENDED: 1
Active Trials (27)
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
Phase 3Recruiting
Enrollment: 860 participants
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
NCT06048484Pancreatic Ductal Adenocarcinoma
Phase 2Recruiting
Enrollment: 60 participants
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
NCT05568095Advanced Upper Gastrointestinal Tract Adenocarcinoma
Phase 3Active
Enrollment: 1,040 participants
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075Advanced Cancer
Phase 1Active
Enrollment: 91 participants
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931Advanced Non-Small Cell Lung Cancer
Phase 2Active
Enrollment: 400 participants
BioScore
4.4/10
Cautious
Ownership
Recent Insider Trades
Jaen Juan C.SELL
2026-06-2431,431 shares @ $27.92
Azoy AlexanderSELL
2026-06-012,562 shares @ $25.77
Goeltz II Robert C.SELL
2026-05-117,763 shares @ $25.63
Jaen Juan C.SELL
2026-01-0531,823 shares @ $21.41
Goeltz II Robert C.SELL
2025-12-316,552 shares @ $23.38
Recent News
2026-07-09 21:00:13
2026-07-01 15:27:00
2026-07-01 15:02:15
2026-06-24 21:00:37
Data last updated: Jul 12, 2026, 07:38 PM